President, Ophthalmology and Chief Medical Officer · OCULAR THERAPEUTIX, INC (OCUL)

Michael Goldstein

A named executive officer of OCULAR THERAPEUTIX in every fiscal year CompBrief holds from FY2018 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$4,061,947

Salary $488,250Stock awards $0Bonus $244,247

FY2020: $1,318,250

2nd of 4 named executive officers at Ocular Therapeutix by FY2021 total.

4 named officers on file for OCULAR THERAPEUTIX, FY2021

Michael Goldstein’s pay file — $29

  • 4 fiscal years of pay, line by line
  • OCUL’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how OCULAR THERAPEUTIX’s whole pay program stands against its peers

  • OCULAR THERAPEUTIX’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on OCUL→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 2, 2022 (DEF 14A).

Free

Get Michael Goldstein’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Michael Goldstein compensation by year

OCULAR THERAPEUTIX Summary Compensation Table · all 4 fiscal years held
In US dollars, as OCULAR THERAPEUTIX reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021
Salary$403,721$423,906$440,000$488,250
Bonus$127,172$126,100$202,400$244,247
Stock awards$0$0$0$0
Option awards$369,429$456,975$675,100$3,326,200
Non-equity incentive$0$0$0$0
Pension and deferred compensation$0$0$0$0
All other$750$750$750$3,250
Total$901,072$1,007,731$1,318,250$4,061,947

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: OCULAR THERAPEUTIX, INC DEF 14A filed May 2, 2022, accession 0001558370-22-006631, and prior-year filings. Open the filing on EDGAR.

How this page was built: the OCULAR THERAPEUTIX, INC filed document, accession 0001558370-22-006631. Every figure is read from that document and cited to the page and table it appears in. Filed May 2, 2022.

$901K
$1.0M
$1.3M
$4.1M
FY18
FY19
FY20
FY21
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option111,981—$4.39
Option1,741—$5.47
Option197,918—$18.31
Option40,627—$4.10

Per the Outstanding Equity Awards at Fiscal Year-End table in OCULAR THERAPEUTIX, INC's FY2021 proxy; value at the fiscal year-end close, as the company printed it.

OCULAR THERAPEUTIX’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Antony MattessichPresident and Chief Executive Officer$7,096,934
Michael Goldstein · this pagePresident, Ophthalmology and Chief Medical Officer$4,061,947
Patricia KitchenFormer Chief Operating Officer$3,388,494
Donald NotmanChief Financial Officer$3,157,079

The full OCULAR THERAPEUTIX compensation record

free company brief

This page is one person within OCULAR THERAPEUTIX's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the OCULAR THERAPEUTIX proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are OCULAR THERAPEUTIX's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Goldstein's compensation dossier · One-time report. No refunds.